इसराइल - हिब्रू - Ministry of Health

medison pharma ltd - dimethyl fumarate - dimethyl fumarate 240 mg - dimetyl fumarate

इसराइल - हिब्रू - Ministry of Health

medison pharma ltd - dimethyl fumarate - dimethyl fumarate 240 mg - dimetyl fumarate

इसराइल - हिब्रू - Ministry of Health

medison pharma ltd - dimethyl fumarate - dimethyl fumarate 240 mg - dimetyl fumarate

इसराइल - हिब्रू - Ministry of Health

teva israel ltd - dimethyl fumarate - dimethyl fumarate 240 mg - dimethyl fumarate

इसराइल - हिब्रू - Ministry of Health

teva israel ltd - dimethyl fumarate - dimethyl fumarate 120 mg - dimethyl fumarate

इसराइल - हिब्रू - Ministry of Health

tzamal bio-pharma ltd - hepatitis b immunoglobulin - תמיסה להזרקה - hepatitis b immunoglobulin 312 iu/ml - hepatitis b immunoglobulin - hepatitis b immunoglobulin - prevention of hepatitis b recurrence following liver transplantation : hepagam b is indicated for the prevetion of hepatitis b recurrence following liver transplantation in hbsag-positive liver transplant patients. hepagam b should be administered intravenously for this indication.postexposure prophylaxis : hepagam b is indicated for the treatment of acute exposure to blood containing hbsag perinatal exposure of infants born to hbsag-positive mothers sexual exposure to hbsag-positive persons and household exposure to persons with acute hbv infection in the following settings: acute exposure to blood containing hbsag following either parenteral exposure (needlestick bite sharps) direct mucous membrane contact (accidental splash) or oral ingestion (pipetting accident) involving hbsag - positive materials such as blood plasma or serum. perinatal exposure of infants born to hbsag-positive mothers infants born to mothers positive for hbsag with or without hbeag. perinatal exposure of infants born to hbsag-positive

इसराइल - हिब्रू - Ministry of Health

אלפא חברה לקוסמטיקה בעמ - מעבה ומדגישה את הריסים

इसराइल - हिब्रू - Ministry of Health

novartis israel ltd - canakinumab - אבקה להכנת תמיסה לזריקה - canakinumab 150 mg / 1 ml - canakinumab - canakinumab - cryopyrin - associated periodic syndromes (caps) in adults, adolescents and children aged 2 years and older with body weight above 7.5 kg, including : - mucle - wells syndrome (mws), - neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca), - severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.gouty arthritis:ilaris is indicated for the symptomatic treatment of adults patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

इसराइल - हिब्रू - Ministry of Health

eli lilly israel ltd, israel - baricitinib - טבליות מצופות פילם - baricitinib 2 mg - baricitinib

इसराइल - हिब्रू - Ministry of Health

eli lilly israel ltd, israel - baricitinib - טבליות מצופות פילם - baricitinib 4 mg - baricitinib